Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04888689
Other study ID # ActiSEP. Part 1.
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 4, 2021
Est. completion date September 30, 2021

Study information

Verified date May 2024
Source Centre Hospitalier Universitaire de Liege
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. We plan to include a group of approximately 20 patients with MS. This study include a unique evaluation in the laboratory of analysis of human movement. A set of tasks will be performed by patients wearing of two magneto-inertial sensors.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed MS diagnosis, - Over 18 years old, - Ambulant patients, - Signed informed consent, - No clinical and / or radiological relapse within 3 months. Exclusion Criteria: - Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection. - Any other previous or present pathology having an impact on motor function. - Recent surgery or trauma (less than 6 months) in the upper or lower limbs

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Actimyo°
Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
IMU
IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope. These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes.

Locations

Country Name City State
Belgium Centre Hospitalier Régional de la Citadelle Liège
Belgium Laboratoire d'Analyse du Mouvement Humain Liège

Sponsors (3)

Lead Sponsor Collaborator
Laurent Servais Centre Hospitalier Régional de la Citadelle, SYSNAV

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary 95th centile of stride velocity 95th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second). One day
Primary 50th centile of stride velocity 50th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second). One day
Primary 95th centile of stride length 95th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter). One day
Primary 50th centile of stride length 50th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter). One day
Primary Stance phase time Stance time over full stride time for each foot obtained with magneto-inertial sensors and a motion capture device (percentage). One day
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4